The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
Earnings call Indivior reported 2025 net revenue of $1.24B (+4% YoY) and record SUBLOCADE revenue of $856M (+13% YoY), with adjusted EBITDA up 20%. For 2026, management guides for mid-teens SUBLOCADE ...
Earnings call Indivior delivered a strong Q1 2026, with total net revenue up 19% year-over-year to $317 million and SUBLOCADE net revenue up 32% to $232 million. Adjusted EBITDA more than doubled, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results